title: Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease.
authors.forename: Gordon K
authors.initials: GK
authors.lastname: Lam
authors.forename: Laura K
authors.initials: LK
authors.lastname: Hummers
authors.forename: Adrianne
authors.initials: A
authors.lastname: Woods
authors.forename: Fredrick M
authors.initials: FM
authors.lastname: Wigley
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D045743:Scleroderma, Diffuse / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D045745:Scleroderma, Limited / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D013585:Synovitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept